Skip to main content
SpringerLink
Log in

Elements of Teratology

  • Chapter
First-Trimester Ultrasound

  • 2192 Accesses

Abstract

Birth defects are not a rare phenomenon, and in most cases are not related to environmental agents. A baseline risk for malformation of 1–3 % is commonly used as a reference frame for evaluating the teratogenic risk of environmental exposures. Environmental factors that have a teratogenic potential include drugs, chemicals, infections, and physical factors such as ionizing radiation. Most environmental agents were not found to have teratogenic potential, and among the drugs that were proven to be teratogenic only few, such as thalidomide and systemic retinoids, exhibit increased risk for malformation of above 20 % when exposure occurred in the sensitive period. Ultrasound can detect a large number of structural anomalies, including many of those reported to be secondary to exposure to potentially teratogenic agents. Despite the fact that only a handful of drugs and other exposures have proven to be teratogenic, women, and in many cases health providers as well, tend to overestimate teratogenic risk. In many cases, overestimation of risk may cause women to discontinue essential medications or alternatively to terminate wanted pregnancies. Therefore, teratogen risk counseling needs to promote evidence-based rather than fear-based decision making.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Moore KL, Persaud TVN, Torchia MG. The developing human: clinically oriented embryology, vol. xiv. 8th ed. Philadelphia, PA: Saunders/Elsevier; 2008. 522.

    Google Scholar 

  2. Koren G, Pastuszak A, Ito S. Drugs in pregnancy. N Engl J Med. 1998;338(16):1128–37.

    CAS  PubMed  Google Scholar 

  3. Heinonen OP, Slone D, Shapiro S. Birth defects and drugs in pregnancy, vol. xi. Littleton, MA: Publishing Sciences Group; 1977. 516.

    Google Scholar 

  4. Nava-Ocampo AA, Koren G. Human teratogens and evidence-based teratogen risk counseling: the Motherisk approach. Clin Obstet Gynecol. 2007;50(1):123–31.

    PubMed  Google Scholar 

  5. Newman CG. Teratogen update: clinical aspects of thalidomide embryopathy – a continuing preoccupation. Teratology. 1985;32(1):133–44.

    CAS  PubMed  Google Scholar 

  6. Smithells RW. Defects and disabilities of thalidomide children. Br Med J. 1973;1(5848):269–72.

    PubMed Central  CAS  PubMed  Google Scholar 

  7. Koren G, Bologa M, Long D, Feldman Y, Shear NH. Perception of teratogenic risk by pregnant women exposed to drugs and chemicals during the first trimester. Am J Obstet Gynecol. 1989;160(5 Pt 1):1190–4.

    CAS  PubMed  Google Scholar 

  8. Walfisch A, Sermer C, Matok I, Einarson A, Koren G. Perception of teratogenic risk and the rated likelihood of pregnancy termination: association with maternal depression. Can J Psychiatry. 2011;56(12):761–7.

    PubMed  Google Scholar 

  9. Neutel CI, Johansen HL. Measuring drug effectiveness by default: the case of Bendectin. Can J Public Health. 1995;86(1):66–70.

    CAS  PubMed  Google Scholar 

  10. Trichopoulos D, Zavitsanos X, Koutis C, Drogari P, Proukakis C, Petridou E. The victims of Chernobyl in Greece: induced abortions after the accident. Br Med J (Clin Res Ed). 1987;295(6606):1100.

    CAS  Google Scholar 

  11. Ketchum LE. Lessons of Chernobyl: SNM members try to decontaminate world threatened by fallout. Part II. J Nucl Med. 1987;28(6):933–42.

    CAS  PubMed  Google Scholar 

  12. Andrade SE, Gurwitz JH, Davis RL, Chan KA, Finkelstein JA, Fortman K, et al. Prescription drug use in pregnancy. Am J Obstet Gynecol. 2004;191(2):398–407.

    PubMed  Google Scholar 

  13. Engeland A, Bramness JG, Daltveit AK, Ronning M, Skurtveit S, Furu K. Prescription drug use among fathers and mothers before and during pregnancy. A population-based cohort study of 106,000 pregnancies in Norway 2004-2006. Br J Clin Pharmacol. 2008;65(5):653–60.

    PubMed Central  PubMed  Google Scholar 

  14. Kutscher AH, Zegarelli EV, Tovell HM, Hochberg B, Hauptman J. Discoloration of deciduous teeth induced by administration of tetracycline antepartum. Am J Obstet Gynecol. 1966;96(2):291–2.

    CAS  PubMed  Google Scholar 

  15. Hendricks SK, Smith JR, Moore DE, Brown ZA. Oligohydramnios associated with prostaglandin synthetase inhibitors in preterm labour. Br J Obstet Gynaecol. 1990;97(4):312–6.

    CAS  PubMed  Google Scholar 

  16. Levin DL. Effects of inhibition of prostaglandin synthesis on fetal development, oxygenation, and the fetal circulation. Semin Perinatol. 1980;4(1):35–44.

    CAS  PubMed  Google Scholar 

  17. Cunniff C, Jones KL, Phillipson J, Benirschke K, Short S, Wujek J. Oligohydramnios sequence and renal tubular malformation associated with maternal enalapril use. Am J Obstet Gynecol. 1990;162(1):187–9.

    CAS  PubMed  Google Scholar 

  18. Chudley AE, Conry J, Cook JL, Loock C, Rosales T, LeBlanc N. Fetal alcohol spectrum disorder: Canadian guidelines for diagnosis. Can Med Assoc J. 2005;172(5 Suppl):S1–21.

    Google Scholar 

  19. Graham Jr JM, Hanson JW, Darby BL, Barr HM, Streissguth AP. Independent dysmorphology evaluations at birth and 4 years of age for children exposed to varying amounts of alcohol in utero. Pediatrics. 1988;81(6):772–8.

    PubMed  Google Scholar 

  20. Mills JL, Graubard BI. Is moderate drinking during pregnancy associated with an increased risk for malformations? Pediatrics. 1987;80(3):309–14.

    CAS  PubMed  Google Scholar 

  21. Sampson PD, Streissguth AP, Bookstein FL, Little RE, Clarren SK, Dehaene P, et al. Incidence of fetal alcohol syndrome and prevalence of alcohol-related neurodevelopmental disorder. Teratology. 1997;56(5):317–26.

    CAS  PubMed  Google Scholar 

  22. Meyer KA, Werler MM, Hayes C, Mitchell AA. Low maternal alcohol consumption during pregnancy and oral clefts in offspring: the Slone Birth Defects Study. Birth Defects Res A Clin Mol Teratol. 2003;67(7):509–14.

    CAS  PubMed  Google Scholar 

  23. Hyoun SC, Obican SG, Scialli AR. Teratogen update: methotrexate. Birth Defects Res A Clin Mol Teratol. 2012;94(4):187–207.

    CAS  PubMed  Google Scholar 

  24. Thiersch JB. Therapeutic abortions with a folic acid antagonist, 4-aminopteroylglutamic acid (4-amino P.G.A) administered by the oral route. Am J Obstet Gynecol. 1952;63(6):1298–304.

    CAS  PubMed  Google Scholar 

  25. Feldkamp M, Carey JC. Clinical teratology counseling and consultation case report: low dose methotrexate exposure in the early weeks of pregnancy. Teratology. 1993;47(6):533–9.

    CAS  PubMed  Google Scholar 

  26. Warkany J. Aminopterin and methotrexate: folic acid deficiency. Teratology. 1978;17(3):353–7.

    CAS  PubMed  Google Scholar 

  27. Del Campo M, Kosaki K, Bennett FC, Jones KL. Developmental delay in fetal aminopterin/methotrexate syndrome. Teratology. 1999;60(1):10–2.

    CAS  PubMed  Google Scholar 

  28. Dolovich LR, Addis A, Vaillancourt JM, Power JD, Koren G, Einarson TR. Benzodiazepine use in pregnancy and major malformations or oral cleft: meta-analysis of cohort and case-control studies. BMJ. 1998;317(7162):839–43.

    PubMed Central  CAS  PubMed  Google Scholar 

  29. Bergman U, Rosa FW, Baum C, Wiholm BE, Faich GA. Effects of exposure to benzodiazepine during fetal life. Lancet. 1992;340(8821):694–6.

    CAS  PubMed  Google Scholar 

  30. Kaaja E, Kaaja R, Hiilesmaa V. Major malformations in offspring of women with epilepsy. Neurology. 2003;60(4):575–9.

    PubMed  Google Scholar 

  31. Artama M, Auvinen A, Raudaskoski T, Isojarvi I, Isojarvi J. Antiepileptic drug use of women with epilepsy and congenital malformations in offspring. Neurology. 2005;64(11):1874–8.

    CAS  PubMed  Google Scholar 

  32. Morrow J, Russell A, Guthrie E, Parsons L, Robertson I, Waddell R, et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry. 2006;77(2):193–8.

    PubMed Central  CAS  PubMed  Google Scholar 

  33. Wide K, Winbladh B, Kallen B. Major malformations in infants exposed to antiepileptic drugs in utero, with emphasis on carbamazepine and valproic acid: a nation-wide, population-based register study. Acta Paediatr. 2004;93(2):174–6.

    CAS  PubMed  Google Scholar 

  34. Meador KJ, Baker GA, Finnell RH, Kalayjian LA, Liporace JD, Loring DW, et al. In utero antiepileptic drug exposure: fetal death and malformations. Neurology. 2006;67(3):407–12.

    PubMed Central  CAS  PubMed  Google Scholar 

  35. Jentink J, Dolk H, Loane MA, Morris JK, Wellesley D, Garne E, et al. Intrauterine exposure to carbamazepine and specific congenital malformations: systematic review and case-control study. BMJ. 2010;341:c6581.

    PubMed Central  PubMed  Google Scholar 

  36. Koren G, Sharav T, Pastuszak A, Garrettson LK, Hill K, Samson I, et al. A multicenter, prospective study of fetal outcome following accidental carbon monoxide poisoning in pregnancy. Reprod Toxicol. 1991;5(5):397–403.

    CAS  PubMed  Google Scholar 

  37. Dadvand P, Rankin J, Rushton S, Pless-Mulloli T. Ambient air pollution and congenital heart disease: a register-based study. Environ Res. 2011;111(3):435–41.

    CAS  PubMed  Google Scholar 

  38. Ritz B, Yu F, Fruin S, Chapa G, Shaw GM, Harris JA. Ambient air pollution and risk of birth defects in Southern California. Am J Epidemiol. 2002;155(1):17–25.

    PubMed  Google Scholar 

  39. Chavez GF, Mulinare J, Cordero JF. Maternal cocaine use during early pregnancy as a risk factor for congenital urogenital anomalies. JAMA. 1989;262(6):795–8.

    CAS  PubMed  Google Scholar 

  40. Frank DA, Zuckerman BS, Amaro H, Aboagye K, Bauchner H, Cabral H, et al. Cocaine use during pregnancy: prevalence and correlates. Pediatrics. 1988;82(6):888–95.

    CAS  PubMed  Google Scholar 

  41. Bingol N, Fuchs M, Diaz V, Stone RK, Gromisch DS. Teratogenicity of cocaine in humans. J Pediatr. 1987;110(1):93–6.

    CAS  PubMed  Google Scholar 

  42. Nulman I, Rovet J, Altmann D, Bradley C, Einarson T, Koren G. Neurodevelopment of adopted children exposed in utero to cocaine. Can Med Assoc J. 1994;151(11):1591–7.

    CAS  Google Scholar 

  43. Kliegman RM, Madura D, Kiwi R, Eisenberg I, Yamashita T. Relation of maternal cocaine use to the risks of prematurity and low birth weight. J Pediatr. 1994;124(5 Pt 1):751–6.

    CAS  PubMed  Google Scholar 

  44. Chasnoff IJ, Burns WJ, Schnoll SH, Burns KA. Cocaine use in pregnancy. N Engl J Med. 1985;313(11):666–9.

    CAS  PubMed  Google Scholar 

  45. Rodriguez-Pinilla E, Martinez-Frias ML. Corticosteroids during pregnancy and oral clefts: a case-control study. Teratology. 1998;58(1):2–5.

    CAS  PubMed  Google Scholar 

  46. Robert E, Vollset SE, Botto L, Lancaster PA, Merlob P, Mastroiacovo P, et al. Malformation surveillance and maternal drug exposure: the MADRE project. Int J Risk Saf Med. 1994;6(2):75–118.

    CAS  PubMed  Google Scholar 

  47. Czeizel AE, Rockenbauer M. Population-based case-control study of teratogenic potential of corticosteroids. Teratology. 1997;56(5):335–40.

    CAS  PubMed  Google Scholar 

  48. Fraser FC, Sajoo A. Teratogenic potential of corticosteroids in humans. Teratology. 1995;51(1):45–6.

    CAS  PubMed  Google Scholar 

  49. Carmichael SL, Shaw GM. Maternal corticosteroid use and risk of selected congenital anomalies. Am J Med Genet. 1999;86(3):242–4.

    CAS  PubMed  Google Scholar 

  50. Park-Wyllie L, Mazzotta P, Pastuszak A, Moretti ME, Beique L, Hunnisett L, et al. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology. 2000;62(6):385–92.

    CAS  PubMed  Google Scholar 

  51. Rayburn WF. Glucocorticoid therapy for rheumatic diseases: maternal, fetal, and breast-feeding considerations. Am J Reprod Immunol. 1992;28(3-4):138–40.

    CAS  PubMed  Google Scholar 

  52. Orr Jr JW, Shingleton HM, Gore H, Austin Jr JM, Hatch KD, Soong SJ. Cervical intraepithelial neoplasia associated with exposure to diethylstilbestrol in utero: a clinical and pathologic study. Obstet Gynecol. 1981;58(1):75–82.

    PubMed  Google Scholar 

  53. Barnes AB, Colton T, Gundersen J, Noller KL, Tilley BC, Strama T, et al. Fertility and outcome of pregnancy in women exposed in utero to diethylstilbestrol. N Engl J Med. 1980;302(11):609–13.

    CAS  PubMed  Google Scholar 

  54. Diav-Citrin O, Shechtman S, Tahover E, Finkel-Pekarsky V, Arnon J, Kennedy D, et al. Pregnancy outcome following in utero exposure to lithium: a prospective, comparative, observational study. Am J Psychiatry. 2014;171(7):785–94.

    PubMed  Google Scholar 

  55. Cohen LS, Friedman JM, Jefferson JW, Johnson EM, Weiner ML. A reevaluation of risk of in utero exposure to lithium. JAMA. 1994;271(2):146–50.

    CAS  PubMed  Google Scholar 

  56. Jacobson SJ, Jones K, Johnson K, Ceolin L, Kaur P, Sahn D, et al. Prospective multicentre study of pregnancy outcome after lithium exposure during first trimester. Lancet. 1992;339(8792):530–3.

    CAS  PubMed  Google Scholar 

  57. Weber-Schoendorfer C, Chambers C, Wacker E, Beghin D, Bernard N, Shechtman S, et al. Pregnancy outcome after methotrexate treatment for rheumatic disease prior to or during early pregnancy: a prospective multicenter cohort study. Arthritis Rheumatol. 2014;66(5):1101–10.

    CAS  PubMed  Google Scholar 

  58. Chapa JB, Hibbard JU, Weber EM, Abramowicz JS, Verp MS. Prenatal diagnosis of methotrexate embryopathy. Obstet Gynecol. 2003;101(5 Pt 2):1104–7.

    PubMed  Google Scholar 

  59. Adam MP, Manning MA, Beck AE, Kwan A, Enns GM, Clericuzio C, et al. Methotrexate/misoprostol embryopathy: report of four cases resulting from failed medical abortion. Am J Med Genet A. 2003;123A(1):72–8.

    PubMed  Google Scholar 

  60. Yedlinsky NT, Morgan FC, Whitecar PW. Anomalies associated with failed methotrexate and misoprostol termination. Obstet Gynecol. 2005;105(5 Pt 2):1203–5.

    PubMed  Google Scholar 

  61. Usta IM, Nassar AH, Yunis KA, Abu-Musa AA. Methotrexate embryopathy after therapy for misdiagnosed ectopic pregnancy. Int J Gynaecol Obstet. 2007;99(3):253–5.

    CAS  PubMed  Google Scholar 

  62. Wheeler M, O’Meara P, Stanford M. Fetal methotrexate and misoprostol exposure: the past revisited. Teratology. 2002;66(2):73–6.

    CAS  PubMed  Google Scholar 

  63. Poggi SH, Ghidini A. Importance of timing of gestational exposure to methotrexate for its teratogenic effects when used in setting of misdiagnosis of ectopic pregnancy. Fertil Steril. 2011;96(3):669–71.

    CAS  PubMed  Google Scholar 

  64. Harada M. Congenital Minamata disease: intrauterine methylmercury poisoning. Teratology. 1978;18(2):285–8.

    CAS  PubMed  Google Scholar 

  65. Amin-Zaki L, Majeed MA, Greenwood MR, Elhassani SB, Clarkson TW, Doherty RA. Methylmercury poisoning in the Iraqi suckling infant: a longitudinal study over five years. J Appl Toxicol. 1981;1(4):210–4.

    CAS  PubMed  Google Scholar 

  66. Marsh DO, Myers GJ, Clarkson TW, Amin-Zaki L, Tikriti S, Majeed MA. Fetal methylmercury poisoning: clinical and toxicological data on 29 cases. Ann Neurol. 1980;7(4):348–53.

    CAS  PubMed  Google Scholar 

  67. Merlob P, Stahl B, Klinger G. Tetrada of the possible mycophenolate mofetil embryopathy: a review. Reprod Toxicol. 2009;28(1):105–8.

    CAS  PubMed  Google Scholar 

  68. Sifontis NM, Coscia LA, Constantinescu S, Lavelanet AF, Moritz MJ, Armenti VT. Pregnancy outcomes in solid organ transplant recipients with exposure to mycophenolate mofetil or sirolimus. Transplantation. 2006;82(12):1698–702.

    CAS  PubMed  Google Scholar 

  69. Hoeltzenbein M, Elefant E, Vial T, Finkel-Pekarsky V, Stephens S, Clementi M, et al. Teratogenicity of mycophenolate confirmed in a prospective study of the European Network of Teratology Information Services. Am J Med Genet A. 2012;158A(3):588–96.

    PubMed  Google Scholar 

  70. Yamashita F, Hayashi M. Fetal PCB syndrome: clinical features, intrauterine growth retardation and possible alteration in calcium metabolism. Environ Health Perspect. 1985;59:41–5.

    PubMed Central  CAS  PubMed  Google Scholar 

  71. Rosa FW. Teratogen update: penicillamine. Teratology. 1986;33(1):127–31.

    CAS  PubMed  Google Scholar 

  72. Hanukoglu A, Curiel B, Berkowitz D, Levine A, Sack J, Lorberboym M. Hypothyroidism and dyshormonogenesis induced by D-penicillamine in children with Wilson’s disease and healthy infants born to a mother with Wilson’s disease. J Pediatr. 2008;153(6):864–6.

    CAS  PubMed  Google Scholar 

  73. Bertollini R, Kallen B, Mastroiacovo P, Robert E. Anticonvulsant drugs in monotherapy. Effect on the fetus. Eur J Epidemiol. 1987;3(2):164–71.

    CAS  PubMed  Google Scholar 

  74. Kjaer D, Horvath-Puho E, Christensen J, Vestergaard M, Czeizel AE, Sorensen HT, et al. Use of phenytoin, phenobarbital, or diazepam during pregnancy and risk of congenital abnormalities: a case-time-control study. Pharmacoepidemiol Drug Saf. 2007;16(2):181–8.

    CAS  PubMed  Google Scholar 

  75. Arpino C, Brescianini S, Robert E, Castilla EE, Cocchi G, Cornel MC, et al. Teratogenic effects of antiepileptic drugs: use of an International Database on Malformations and Drug Exposure (MADRE). Epilepsia. 2000;41(11):1436–43.

    CAS  PubMed  Google Scholar 

  76. Waters CH, Belai Y, Gott PS, Shen P, De Giorgio CM. Outcomes of pregnancy associated with antiepileptic drugs. Arch Neurol. 1994;51(3):250–3.

    CAS  PubMed  Google Scholar 

  77. Smith DW. Teratogenicity of anticonvulsive medications. Am J Dis Child. 1977;131(12):1337–9.

    CAS  PubMed  Google Scholar 

  78. Harden CL, Meador KJ, Pennell PB, Hauser WA, Gronseth GS, French JA, et al. Management issues for women with epilepsy-Focus on pregnancy (an evidence-based review): II. Teratogenesis and perinatal outcomes: report of the Quality Standards Subcommittee and Therapeutics and Technology Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Epilepsia. 2009;50(5):1237–46.

    PubMed  Google Scholar 

  79. Berard A, Azoulay L, Koren G, Blais L, Perreault S, Oraichi D. Isotretinoin, pregnancies, abortions and birth defects: a population-based perspective. Br J Clin Pharmacol. 2007;63(2):196–205.

    PubMed Central  PubMed  Google Scholar 

  80. Lammer EJ, Chen DT, Hoar RM, Agnish ND, Benke PJ, Braun JT, et al. Retinoic acid embryopathy. N Engl J Med. 1985;313(14):837–41.

    CAS  PubMed  Google Scholar 

  81. Samren EB, van Duijn CM, Koch S, Hiilesmaa VK, Klepel H, Bardy AH, et al. Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint European prospective study of human teratogenesis associated with maternal epilepsy. Epilepsia. 1997;38(9):981–90.

    CAS  PubMed  Google Scholar 

  82. Centers for Disease Control (CDC). Valproic acid and spina bifida: a preliminary report – France. MMWR Morb Mortal Wkly Rep. 1982;31(42):565–6.

    Google Scholar 

  83. Centers for Disease Control (CDC). Valproate: a new cause of birth defects – report from Italy and follow-up from France. MMWR Morb Mortal Wkly Rep. 1983;32(33):438–9.

    Google Scholar 

  84. Jentink J, Loane MA, Dolk H, Barisic I, Garne E, Morris JK, et al. Valproic acid monotherapy in pregnancy and major congenital malformations. N Engl J Med. 2010;362(23):2185–93.

    CAS  PubMed  Google Scholar 

  85. Hall JG, Pauli RM, Wilson KM. Maternal and fetal sequelae of anticoagulation during pregnancy. Am J Med. 1980;68(1):122–40.

    CAS  PubMed  Google Scholar 

  86. Iturbe-Alessio I, Fonseca MC, Mutchinik O, Santos MA, Zajarias A, Salazar E. Risks of anticoagulant therapy in pregnant women with artificial heart valves. N Engl J Med. 1986;315(22):1390–3.

    CAS  PubMed  Google Scholar 

  87. Ville Y, Jenkins E, Shearer MJ, Hemley H, Vasey DP, Layton M, et al. Fetal intraventricular haemorrhage and maternal warfarin. Lancet. 1993;341(8854):1211.

    CAS  PubMed  Google Scholar 

  88. Chan WS, Anand S, Ginsberg JS. Anticoagulation of pregnant women with mechanical heart valves: a systematic review of the literature. Arch Intern Med. 2000;160(2):191–6.

    CAS  PubMed  Google Scholar 

  89. Raynor BD. Cytomegalovirus infection in pregnancy. Semin Perinatol. 1993;17(6):394–402.

    CAS  PubMed  Google Scholar 

  90. Brown HL, Abernathy MP. Cytomegalovirus infection. Semin Perinatol. 1998;22(4):260–6.

    CAS  PubMed  Google Scholar 

  91. Hedrick J. The effects of human parvovirus B19 and cytomegalovirus during pregnancy. J Perinat Neonatal Nurs. 1996;10(2):30–9.

    CAS  PubMed  Google Scholar 

  92. Bodeus M, Hubinont C, Goubau P. Increased risk of cytomegalovirus transmission in utero during late gestation. Obstet Gynecol. 1999;93(5 Pt 1):658–60.

    CAS  PubMed  Google Scholar 

  93. Fowler KB, Stagno S, Pass RF, Britt WJ, Boll TJ, Alford CA. The outcome of congenital cytomegalovirus infection in relation to maternal antibody status. N Engl J Med. 1992;326(10):663–7.

    CAS  PubMed  Google Scholar 

  94. Gratacos E, Torres PJ, Vidal J, Antolin E, Costa J, Jimenez de Anta MT. The incidence of human parvovirus B19 infection during pregnancy and its impact on perinatal outcome. J Infect Dis. 1995;171(5):1360–3.

    CAS  PubMed  Google Scholar 

  95. Public Health Laboratory Service Working Party on Fifth Disease. Prospective study of human parvovirus (B19) infection in pregnancy. BMJ. 1990;300(6733):1166–70

    Google Scholar 

  96. Markenson GR, Yancey MK. Parvovirus B19 infections in pregnancy. Semin Perinatol. 1998;22(4):309–17.

    CAS  PubMed  Google Scholar 

  97. Control and prevention of rubella: evaluation and management of suspected outbreaks, rubella in pregnant women, and surveillance for congenital rubella syndrome. MMWR Morb Mortal Wkly Rep. 2001;50(RR-12):1–23

    Google Scholar 

  98. Reef SE, Plotkin S, Cordero JF, Katz M, Cooper L, Schwartz B, et al. Preparing for elimination of congenital Rubella syndrome (CRS): summary of a workshop on CRS elimination in the United States. Clin Infect Dis. 2000;31(1):85–95.

    CAS  PubMed  Google Scholar 

  99. Webster WS. Teratogen update: congenital rubella. Teratology. 1998;58(1):13–23.

    CAS  PubMed  Google Scholar 

  100. McIntosh ED, Menser MA. A fifty-year follow-up of congenital rubella. Lancet. 1992;340(8816):414–5.

    CAS  PubMed  Google Scholar 

  101. Dunn D, Wallon M, Peyron F, Petersen E, Peckham C, Gilbert R. Mother-to-child transmission of toxoplasmosis: risk estimates for clinical counselling. Lancet. 1999;353(9167):1829–33.

    CAS  PubMed  Google Scholar 

  102. McAuley J, Boyer KM, Patel D, Mets M, Swisher C, Roizen N, et al. Early and longitudinal evaluations of treated infants and children and untreated historical patients with congenital toxoplasmosis: the Chicago Collaborative Treatment Trial. Clin Infect Dis. 1994;18(1):38–72.

    CAS  PubMed  Google Scholar 

  103. Koppe JG, Loewer-Sieger DH, de Roever-Bonnet H. Results of 20-year follow-up of congenital toxoplasmosis. Lancet. 1986;1(8475):254–6.

    CAS  PubMed  Google Scholar 

  104. Wilson CB, Remington JS, Stagno S, Reynolds DW. Development of adverse sequelae in children born with subclinical congenital Toxoplasma infection. Pediatrics. 1980;66(5):767–74.

    CAS  PubMed  Google Scholar 

  105. Goldenberg RL, Thompson C. The infectious origins of stillbirth. Am J Obstet Gynecol. 2003;189(3):861–73.

    PubMed  Google Scholar 

  106. Saxoni F, Lapaanis P, Pantelakis SN. Congenital syphilis: a description of 18 cases and re-examination of an old but ever-present disease. Clin Pediatr. 1967;6(12):687–91.

    CAS  Google Scholar 

  107. Whitaker JA, Sartain P, Shaheedy M. Hematological aspects of congenital syphilis. J Pediatr. 1965;66:629–36.

    CAS  PubMed  Google Scholar 

  108. Smith CK, Arvin AM. Varicella in the fetus and newborn. Semin Fetal Neonatal Med. 2009;14(4):209–17.

    PubMed  Google Scholar 

  109. Tan MP, Koren G. Chickenpox in pregnancy: revisited. Reprod Toxicol. 2006;21(4):410–20.

    CAS  PubMed  Google Scholar 

  110. Sanchez MA, Bello-Munoz JC, Cebrecos I, Sanz TH, Martinez JS, Moratonas EC, et al. The prevalence of congenital varicella syndrome after a maternal infection, but before 20 weeks of pregnancy: a prospective cohort study. J Matern Fetal Neonatal Med. 2011;24(2):341–7.

    PubMed  Google Scholar 

  111. Harger JH, Ernest JM, Thurnau GR, Moawad A, Thom E, Landon MB, et al. Frequency of congenital varicella syndrome in a prospective cohort of 347 pregnant women. Obstet Gynecol. 2002;100(2):260–5.

    PubMed  Google Scholar 

  112. Gilbert GL. Chickenpox during pregnancy. BMJ. 1993;306(6885):1079–80.

    PubMed Central  CAS  PubMed  Google Scholar 

  113. Dekaban AS. Abnormalities in children exposed to x-radiation during various stages of gestation: tentative timetable of radiation injury to the human fetus. I. J Nucl Med. 1968;9(9):471–7.

    CAS  PubMed  Google Scholar 

  114. Miller RW. Delayed radiation effects in atomic-bomb survivors. Major observations by the Atomic Bomb Casualty Commission are evaluated. Science. 1969;166(3905):569–74.

    CAS  PubMed  Google Scholar 

  115. Plummer G. Anomalies occurring in children exposed in utero to the atomic bomb in Hiroshima. Pediatrics. 1952;10(6):687–93.

    CAS  PubMed  Google Scholar 

  116. Wood JW, Johnson KG, Omori Y. In utero exposure to the Hiroshima atomic bomb. An evaluation of head size and mental retardation: twenty years later. Pediatrics. 1967;39(3):385–92.

    CAS  PubMed  Google Scholar 

  117. Jankowski CB. Radiation and pregnancy. Putting the risks in proportion. Am J Nurs. 1986;86(3):260–5.

    CAS  PubMed  Google Scholar 

  118. Lione A. Ionizing radiation and human reproduction. Reprod Toxicol. 1987;1(1):3–16.

    CAS  PubMed  Google Scholar 

  119. Russell LB, Russell WL. An analysis of the changing radiation response of the developing mouse embryo. J Cell Physiol Suppl. 1954;43 Suppl 1:103–49.

    CAS  PubMed  Google Scholar 

  120. Rowley KA, Hill SJ, Watkins RA, Moores BM. An investigation into the levels of radiation exposure in diagnostic examinations involving fluoroscopy. Br J Radiol. 1987;60(710):167–73.

    CAS  PubMed  Google Scholar 

  121. Koren G. Medication safety in pregnancy and breastfeeding, vol. xv. New York, NY: McGraw-Hill, Health Professions Division; 2007. 623.

    Google Scholar 

  122. Cibull SL, Harris GR, Nell DM. Trends in diagnostic ultrasound acoustic output from data reported to the US Food and Drug Administration for device indications that include fetal applications. J Ultrasound Med. 2013;32(11):1921–32.

    PubMed  Google Scholar 

  123. Sheiner E, Abramowicz JS. A symposium on obstetrical ultrasound: is all this safe for the fetus? Clin Obstet Gynecol. 2012;55(1):188–98.

    PubMed  Google Scholar 

  124. Bly S, Van den Hof MC. Obstetric ultrasound biological effects and safety. J Obstet Gynaecol Can. 2005;27(6):572–80.

    PubMed  Google Scholar 

  125. Abramowicz JS. Benefits and risks of ultrasound in pregnancy. Semin Perinatol. 2013;37(5):295–300.

    PubMed  Google Scholar 

  126. Hellman LM, Duffus GM, Donald I, Sunden B. Safety of diagnostic ultrasound in obstetrics. Lancet. 1970;1(7657):1133–4.

    CAS  PubMed  Google Scholar 

  127. Scheidt PC, Stanley F, Bryla DA. One-year follow-up of infants exposed to ultrasound in utero. Am J Obstet Gynecol. 1978;131(7):743–8.

    CAS  PubMed  Google Scholar 

  128. Stark CR, Orleans M, Haverkamp AD, Murphy J. Short- and long-term risks after exposure to diagnostic ultrasound in utero. Obstet Gynecol. 1984;63(2):194–200.

    CAS  PubMed  Google Scholar 

  129. Wilson MK. Obstetric ultrasound and childhood malignancies. Radiography. 1985;51(600):319–20.

    CAS  PubMed  Google Scholar 

  130. Smith DP, Graham JB, Prystowsky JB, Dalkin BL, Nemcek Jr AA. The effects of ultrasound-guided shock waves during early pregnancy in Sprague-Dawley rats. J Urol. 1992;147(1):231–4.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Motherisk Program, Division of Clinical Pharmacology and Toxicology, The Hospital for Sick Children, 555 University Avenue, Toronto, ON, Canada, M5G 1X8

    Eran Barzilay MD, PhD & Gideon Koren MD, FRCPC, FACMT, FAACT

Authors
  1. Eran Barzilay MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gideon Koren MD, FRCPC, FACMT, FAACT
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gideon Koren MD, FRCPC, FACMT, FAACT .

Editor information

Editors and Affiliations

  1. Division of Maternal-Fetal Medicine Department of Obstetrics and Gynecology, Wayne State University School of Medicine, Detroit, Michigan, USA

    Jacques S. Abramowicz

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Barzilay, E., Koren, G. (2016). Elements of Teratology. In: Abramowicz, J. (eds) First-Trimester Ultrasound. Springer, Cham. https://doi.org/10.1007/978-3-319-20203-7_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-20203-7_5

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-20202-0

  • Online ISBN: 978-3-319-20203-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation